Zhang X, et al. - Among gastrointestinal stromal tumor (GIST) patients undergoing R0 resection or optimal cytoreductive surgery, researchers determined progression-free survival (PFS) when with sunitinib therapy vs imatinib following tumor unifocal or multifocal progression. They analyzed 97 patients from thirteen medical centers from January 2006 to June 2017. Outcomes suggested an improved PFS in relation to surgery followed by sunitinib in GIST patients with unifocal or multifocal progression on imatinib, vs surgery followed by imatinib.